MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
Immutep Limited Total Liabilities 2011-2026 | IMMP
Annual Total Liabilities Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 12.1 M | 11 M | 8.09 M | 8.76 M | 13.3 M | 16.2 M | 13.5 M | 8.43 M | 7.24 M | 6.29 M | 2.79 M | 3.57 M | 4.45 M | 2.54 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | 2.54 M | 8.76 M |
Quarterly Total Liabilities Immutep Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.76 M | - | - | - | 13.3 M | - | - | - | 16.2 M | - | - | - | 13.5 M | - | - | - | 8.43 M | - | - | - | 7.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | 7.24 M | 11.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
35 M | $ 8.48 | 6.0 % | $ 83.8 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 2.19 | 0.92 % | $ 455 M | USA |
 |
Evogene Ltd.
EVGN
|
8.07 M | $ 0.78 | -4.39 % | $ 27.9 M |  Israel |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Genmab A/S
GMAB
|
2.02 B | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.38 | 2.01 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
1.32 M | $ 0.38 | 2.47 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 21.28 | 4.44 % | $ 995 M | USA |
 |
Halozyme Therapeutics
HALO
|
2.48 B | $ 66.92 | -1.33 % | $ 8.02 B | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
401 M | $ 29.05 | 0.55 % | $ 1.67 B | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Incyte Corporation
INCY
|
1.79 B | $ 95.33 | -0.77 % | $ 18.6 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.46 | 4.29 % | $ 375 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.99 | 2.4 % | $ 4.92 M | Israel |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.2 | 2.82 % | $ 449 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.24 | 0.1 % | $ 3.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
151 M | $ 1.47 | 4.26 % | $ 235 M | France |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |